Finanzen von Seaport Therapeutics Inc (SPTX)SPTXSeaport Therapeutics Inc

In the context of the broader market, SPTX competes directly with industry leaders such as NBTX and MNKD. With a market capitalization of $1.11B, it holds a significant position in the sector. When comparing efficiency, SPTX's gross margin of N/A stands against NBTX's 100.00% and MNKD's 69.00%. Such benchmarking helps identify whether Seaport Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Seaport Therapeutics has shown a significant increase in total equity from $209.7 million in Q1 2026 to $422.6 million in Q2 2026, indicating a strong financial position despite ongoing losses. The current ratio has also improved to 18.00, suggesting good liquidity.